| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
693,731 |
518,693 |
$66.36M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
887,120 |
494,866 |
$49.21M |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
280,911 |
178,304 |
$38.39M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
229,541 |
195,753 |
$14.85M |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
106,876 |
78,454 |
$13.36M |
| 99215 |
Prolong outpt/office vis |
83,252 |
62,796 |
$12.63M |
| H0016 |
Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) |
97,349 |
64,900 |
$12.34M |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
115,729 |
88,172 |
$11.12M |
| 82075 |
|
500,003 |
302,011 |
$11.07M |
| Q3014 |
Telehealth originating site facility fee |
356,810 |
295,435 |
$8.25M |
| H0001 |
Alcohol and/or drug assessment |
12,023 |
11,769 |
$6.50M |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
34,464 |
30,048 |
$4.96M |
| 99205 |
Prolong outpt/office vis |
12,754 |
12,146 |
$2.12M |
| 80361 |
|
20,431 |
11,872 |
$628K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
15,171 |
14,186 |
$495K |
| 80346 |
|
20,385 |
11,866 |
$493K |
| 80348 |
|
20,762 |
12,043 |
$489K |
| 80354 |
|
20,475 |
11,898 |
$482K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
14,062 |
13,135 |
$456K |
| 80324 |
|
20,400 |
11,844 |
$389K |
| 80362 |
|
16,592 |
9,787 |
$380K |
| 80365 |
|
16,308 |
9,432 |
$376K |
| 81025 |
|
61,102 |
32,099 |
$364K |
| 80358 |
|
14,947 |
8,627 |
$348K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
10,419 |
9,686 |
$338K |
| 80074 |
|
7,355 |
6,713 |
$280K |
| 80345 |
|
11,397 |
6,275 |
$247K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
8,666 |
7,861 |
$184K |
| H0047 |
Alcohol and/or other drug abuse services, not otherwise specified |
335 |
206 |
$157K |
| 80353 |
|
7,558 |
5,123 |
$148K |
| 80323 |
|
14,452 |
8,205 |
$145K |
| 80356 |
|
13,873 |
7,811 |
$134K |
| 80355 |
|
18,111 |
10,468 |
$117K |
| H2036 |
Alcohol and/or other drug treatment program, per diem |
155 |
109 |
$116K |
| 80373 |
|
14,454 |
8,226 |
$108K |
| 86780 |
|
8,899 |
8,090 |
$105K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
693 |
674 |
$95K |
| 86708 |
|
7,505 |
6,856 |
$83K |
| 86704 |
|
7,411 |
6,804 |
$78K |
| 86706 |
|
7,796 |
7,122 |
$74K |
| 80076 |
|
9,563 |
8,713 |
$66K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
9,163 |
8,329 |
$66K |
| 80368 |
|
12,463 |
6,974 |
$60K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
8,512 |
7,726 |
$59K |
| 80366 |
|
11,537 |
6,282 |
$49K |
| 80369 |
|
9,827 |
5,171 |
$39K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,236 |
3,817 |
$37K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,336 |
2,043 |
$34K |
| H0034 |
Medication training and support, per 15 minutes |
983 |
643 |
$33K |
| 80321 |
|
6,919 |
4,152 |
$25K |
| 80305 |
|
2,037 |
723 |
$24K |
| H2035 |
Alcohol and/or other drug treatment program, per hour |
33 |
25 |
$23K |
| 36415 |
Collection of venous blood by venipuncture |
10,695 |
9,744 |
$22K |
| H0050 |
Alcohol and/or drug services, brief intervention, per 15 minutes |
21 |
12 |
$20K |
| 84439 |
|
2,341 |
2,047 |
$18K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
309 |
305 |
$18K |
| 80360 |
|
2,032 |
1,412 |
$12K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
127 |
127 |
$11K |
| 80349 |
|
946 |
687 |
$8K |
| T1016 |
Case management, each 15 minutes |
879 |
812 |
$7K |
| 80359 |
|
382 |
268 |
$6K |
| 86803 |
|
335 |
276 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
75 |
74 |
$3K |
| 99406 |
|
331 |
142 |
$3K |
| 80357 |
|
387 |
274 |
$2K |
| 80372 |
|
299 |
214 |
$2K |
| 80371 |
|
383 |
278 |
$2K |
| 80061 |
Lipid panel |
75 |
67 |
$889.87 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
12 |
12 |
$826.78 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
13 |
13 |
$650.56 |
| 86705 |
|
23 |
15 |
$161.40 |
| 87340 |
|
23 |
15 |
$141.64 |